The Evolving Landscape of Factor Replacement Therapy – EAHAD
European Association for Haemophilia and Allied Disorders (EAHAD) shared a post onĀ LinkedIn:
“Summer is the perfect time to catch up on the educational content you’ve been meaning to watch and stay up to date with the latest developments in haemophilia care.
One topic that continues to evolve rapidly is factor replacement therapy.
As treatment options expand, choosing the most appropriate factor VIII and factor IX replacement products and understanding how monitoring is changing has become increasingly important for delivering personalised care.
In this recorded session, Jan Astermark, Annette Bowyer and Cedric Hermans (Lon,Edin) examine the latest evidence, discuss the expanding therapeutic landscape, and explore how monitoring is evolving to support more precise, individualised treatment decisions.
What session is next on your summer learning list?”
Other posts about European Association for Haemophilia and Allied Disorders on Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?